Amneal Pharmaceuticals, Inc. (AMRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Amneal Pharmaceuticals reported revenue of $3.02B, up 8.0% from $2.79B the year before. Net income was $72.1M (a 2.4% net margin), or $0.22 per diluted share. Gross margin was 36.9% and operating margin was 13.1%. Operating activities generated $340.0M of cash, leaving $269.9M of free cash flow. At fiscal year end, Amneal Pharmaceuticals held $3.68B in total assets against $3.75B in total liabilities, including $282.0M of cash and equivalents.
Open the full interactive Amneal Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Amneal Pharmaceuticals Key Stats
| Share Price | $19.57 |
|---|---|
| Market Cap | $6.42B |
| P/E Ratio | 89.0 |
| Revenue YoY Growth | +8.1% |
| 52-Week Range | $9.72 – $20.50 |
| Shares Outstanding | 319.2 million (basic, 2026 Q2) |
Amneal Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.99B | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B |
| Cost of Goods Sold | $1.33B | $1.30B | $1.42B | $1.57B | $1.77B | $1.91B |
| Gross Profit | $628.4M | $769.0M | $784.7M | $820.6M | $1.02B | $1.11B |
| Operating Income | $91.2M | $152.7M | -$94.9M | $204.4M | $249.3M | $394.1M |
| Pre-Tax Income | -$35.8M | $31.4M | -$248.1M | -$40.3M | -$55.0M | $139.2M |
| Income Tax | -$104.4M | $11.2M | $6.7M | $8.5M | $18.9M | $11.3M |
| Net Income | $91.1M | $13.2M | -$270.6M | -$79.3M | -$116.9M | $72.1M |
| Diluted EPS | $0.61 | $0.07 | -$0.86 | -$0.48 | -$0.38 | $0.22 |
Amneal Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $784.5M | $814.3M | $722.5M | $796.2M |
| Net Income | $2.4M | $35.1M | $62.3M | $57.7M |
| Diluted EPS | $0.01 | $0.11 | $0.19 | $0.18 |
Amneal Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $341.4M | $247.8M | $26.0M | $91.5M | $110.6M | $282.0M |
| Current Assets | $1.55B | $1.52B | $1.41B | $1.38B | $1.59B | $1.91B |
| Total Assets | $4.01B | $3.94B | $3.80B | $3.47B | $3.50B | $3.68B |
| Current Liabilities | $676.9M | $677.2M | $752.8M | $846.6M | $1.13B | $881.6M |
| Total Long-Term Debt | $2.78B | $2.71B | $2.62B | $2.42B | $2.39B | $2.57B |
| Total Liabilities | $3.70B | $3.58B | $3.50B | $3.45B | $3.61B | $3.75B |
| Shareholders' Equity | $303.3M | $360.3M | $298.4M | $19.8M | -$109.3M | -$70.8M |
Amneal Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $379.0M | $241.8M | $65.1M | $345.6M | $295.1M | $340.0M |
| Cash From Investing | -$317.5M | -$194.2M | -$174.3M | -$69.2M | -$63.0M | -$112.3M |
| Cash From Financing | $131.8M | -$138.1M | -$106.6M | -$212.6M | -$211.8M | -$31.5M |
| Free Cash Flow | $322.6M | $194.1M | $18.7M | $302.4M | $243.2M | $269.9M |
| Dividends Paid | $0 | — | — | — | — | — |
Figures from Amneal Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Amneal Pharmaceuticals financials page for every line item.
Amneal Pharmaceuticals Company Profile
| Ticker | AMRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001723128 |
Frequently Asked Questions
What was Amneal Pharmaceuticals' revenue in fiscal 2025?
Amneal Pharmaceuticals (AMRX) reported revenue of $3.02B for fiscal 2025.
What is Amneal Pharmaceuticals' annual revenue history?
Amneal Pharmaceuticals' annual revenue by fiscal year: 2020: $1.99B; 2021: $2.09B; 2022: $2.21B; 2023: $2.39B; 2024: $2.79B; 2025: $3.02B.
What was Amneal Pharmaceuticals' net income in fiscal 2025?
Amneal Pharmaceuticals reported net income of $72.1M for fiscal 2025.
What was Amneal Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Amneal Pharmaceuticals' diluted EPS was $0.22 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Amneal Pharmaceuticals generate in fiscal 2025?
Amneal Pharmaceuticals generated $269.9M of free cash flow in fiscal 2025.
What was Amneal Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Amneal Pharmaceuticals reported revenue of $796.2M.
How much debt does Amneal Pharmaceuticals have?
Amneal Pharmaceuticals reported $2.57B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Amneal Pharmaceuticals are outstanding?
Amneal Pharmaceuticals reported a weighted average of 319.2 million basic shares outstanding in 2026 Q2.
What is Amneal Pharmaceuticals' market cap?
Based on its latest closing price, Amneal Pharmaceuticals (AMRX) has a market capitalization of about $6.42B.
When does Amneal Pharmaceuticals' fiscal year end?
Amneal Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.